Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome

Next Previous
X
Search
Trial Profile

An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Atypical Haemolytic Uraemic Syndrome
  • Focus Therapeutic Use
  • Sponsors Alexion Pharmaceuticals

    • Most Recent Events

    • 12 Dec 2021 Results of patient-level data from four eculizumab clinical trials (C08-002A/B (NCT00844545/NCT00844844), C10-003 (NCT01193348), and C10-004 (NCT01194973) were available for pooling and comparison with data from two ravulizumab trials (ALXN-aHUS-311 (NCT02949128) and ALXN-aHUS-312 (NCT03131219) assessing the effectiveness of ravulizumab and eculizumab for the treatment of aHUS, accounting for observed differences between clinical studies, published in the Clinical Nephrology.
    • 05 May 2014 The US FDA has approved Alexion Pharmaceuticals' supplemental Biologics License Application (sBLA) providing regular approval for eculizumab; regular approval includes data from this study.
    • 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top